Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06581406 · ClinicalTrials.gov registry record · Phase 2

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

A Phase 2 study of Metastatic Uveal Melanoma, sponsored by Replimune.

Recruiting
Registry status
Phase 2
Development phase
280
Enrollment target
20
Study locations

NCT06581406 is a Phase 2 study of Metastatic Uveal Melanoma that is actively recruiting participants, run by Replimune. The registered enrollment target is 280 participants, above the 113-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (148% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06581406, a Phase 2 study of Metastatic Uveal Melanoma, is actively recruiting participants, sponsored by Replimune.

RECRUITING
Registry status
Phase 2
Development phase
280 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.

Conditions Studied

Metastatic Uveal Melanoma

Interventions

  • BIOLOGICAL Nivolumab
  • BIOLOGICAL Ipilimumab
  • BIOLOGICAL RP2

Study Locations (20)

California

  • UC San Diego Moores Cancer Center - La Jolla
  • The Angeles Clinic and Research Institute - Los Angeles
  • University of California Los Angeles - Los Angeles
  • Stanford Cancer Institute - Palo Alto

Colorado

  • University of Colorado Hospital - Anschutz Cancer Pavilion(ACP) - Aurora
  • The Melanoma & Skin Cancer Institute - Englewood

Florida

  • Mayo Clinic - Jacksonville FL - Jacksonville
  • Sylvester Comprehensive Cancer Center - Miami

Illinois

  • Northwestern Memorial Hospital - Chicago
  • University of Chicago Medical Center - Chicago

Arizona

  • HonorHealth Research Insisute - Scottsdale

District of Columbia

  • Georgetown University Medical Center - Washington D.C.

Georgia

  • Emory Winship Cancer Institute - Atlanta

Iowa

  • University of Iowa - Iowa City

Trial Details

FieldValue
Enrollment Target 280 participants
Start Date 2024-12-17
Est. Completion 2031-10
Phase Phase 2

Sponsor

Replimune

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06581406

The ClinicalTrials.gov registry entry for NCT06581406 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 280 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 113-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (148% higher). The listed sponsor is Replimune, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.

NCT06581406 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Colorado, Florida.

Frequently Asked Questions

What is clinical trial NCT06581406 about?

NCT06581406 is a clinical study titled "A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma". The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.

What is the current status of trial NCT06581406?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2024-12-17. Estimated completion is 2031-10.

What conditions does trial NCT06581406 study?

This clinical trial studies the following conditions: Metastatic Uveal Melanoma.

What interventions are being tested in trial NCT06581406?

The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), RP2 (BIOLOGICAL).

Who is sponsoring clinical trial NCT06581406?

This trial is sponsored by Replimune, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06581406 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Uveal Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Uveal Melanoma

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.